Search
for
Sort by
Research 61–90 of 1000+
- Tyrosine kinase Inhibitors in Dermatology: A Systemic Review
- Alopecia Areata
- The Role of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo: A Review article
- Precision therapeutics in non-scarring alopecia: a systemic genomic and pathway-based framework for targeted interventions
- Discontinuation and restart of Janus kinase inhibitors due to pregnancy in alopecia areata: a case series
- Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review
- Analyzing the role of tofacitinib in treatment of alopecia areata: A retrospective analysis from a tertiary care center of North India
- A Novel Hope for Alopecia Totalis Patients: Case Report
- The functions of ocu-miR-205 in regulating hair follicle development in Rex rabbits
- Effects of the RV3466F lotion on female telogen effluvium: Results from a 16 week, multi-centric, controlled, randomized trial
- Common questions and misconceptions about creatine supplementation: what does the scientific evidence really show?
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Haff disease associated with the ingestion of the freshwater fish Mylossoma duriventre (pacu-manteiga)
- Evaluation of the Tolerability of Hedgehog Pathway Inhibitors in the Treatment of Advanced Basal Cell Carcinoma: A Narrative Review of Treatment Strategies
- Janus kinase inhibitors for alopecia areata: a review of clinical data
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
- Evidence for the off-label use of tofacitinib in alopecia areata
- Ritlecitinib: First Approval
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Suspected upadacitinib-associated drug hypersensitivity mimicking disease exacerbation in ulcerative colitis
- The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
- TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Baicalin increases hair follicle development by increasing canonical Wnt/β‑catenin signaling and activating dermal papillar cells in mice
- Skin-specific regulation of SREBP processing and lipid biosynthesis by glycerol kinase 5
- An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature
- Pyruvate Kinase M2 Accelerates Cutaneous Wound Healing via Glycolysis and Wnt/β-Catenin Signaling